INCHEON, South Korea and CAMBRIDGE, MA, USA I November 18, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...

The annual meeting of the American Society of Nephrology (Kidney Week) was held this year from Oct. 23 to 27 in San Diego, ...

Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.

Kennedy, an anti-vaccine activist, reportedly said Trump had “promised” him “control” of the country’s public health agencies ...